IMGN 632

Drug Profile

IMGN 632

Alternative Names: Anti-CD123 antibody; IMGN632

Latest Information Update: 12 Dec 2016

Price : $50

At a glance

  • Originator ImmunoGen
  • Class Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Alkylating agents; Interleukin-3-receptor-alpha-subunit-antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies

Most Recent Events

  • 28 Oct 2016 Immunogen plans a clinical trial for Haematological malignancies in 2017
  • 04 Aug 2016 ImmunoGen plans to file an IND application with the US FDA for Haematological malignancies in 2017
  • 27 Jun 2016 Preclinical trials in Haematological malignancies in USA (ImmunoGen's website, August 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top